Predicting Patterns of Long-Term CD4 Reconstitution in HIV-Infected Children Starting Antiretroviral Therapy in Sub-Saharan Africa: A Cohort-Based Modelling Study

English version České info

Background:
Long-term immune reconstitution on antiretroviral therapy (ART) has important implications for HIV-infected children, who increasingly survive into adulthood. Children's response to ART differs from adults', and better descriptive and predictive models of reconstitution are needed to guide policy and direct research. We present statistical models characterising, qualitatively and quantitatively, patterns of long-term CD4 recovery.

Methods and Findings:
CD4 counts every 12 wk over a median (interquartile range) of 4.0 (3.7, 4.4) y in 1,206 HIV-infected children, aged 0.4–17.6 y, starting ART in the Antiretroviral Research for Watoto trial (ISRCTN 24791884) were analysed in an exploratory analysis supplementary to the trial's pre-specified outcomes. Most (n = 914; 76%) children's CD4 counts rose quickly on ART to a constant age-corrected level. Using nonlinear mixed-effects models, higher long-term CD4 counts were predicted for children starting ART younger, and with higher CD4 counts (p<0.001). These results suggest that current World Health Organization–recommended CD4 thresholds for starting ART in children ≥5 y will result in lower CD4 counts in older children when they become adults, such that vertically infected children who remain ART-naïve beyond 10 y of age are unlikely ever to normalise CD4 count, regardless of CD4 count at ART initiation. CD4 profiles with four qualitatively distinct reconstitution patterns were seen in the remaining 292 (24%) children. Study limitations included incomplete viral load data, and that the uncertainty in allocating children to distinct reconstitution groups was not modelled.

Conclusions:
Although younger ART-naïve children are at high risk of disease progression, they have good potential for achieving high CD4 counts on ART in later life provided ART is initiated following current World Health Organization (WHO), Paediatric European Network for Treatment of AIDS, or US Centers for Disease Control and Prevention guidelines. In contrast, to maximise CD4 reconstitution in treatment-naïve children >10 y, ART should ideally be considered even if there is a low risk of immediate disease progression. Further exploration of the immunological mechanisms for these CD4 recovery profiles should help guide management of paediatric HIV infection and optimise children's immunological development.

Please see later in the article for the Editors' Summary

Vyšlo v časopise: Predicting Patterns of Long-Term CD4 Reconstitution in HIV-Infected Children Starting Antiretroviral Therapy in Sub-Saharan Africa: A Cohort-Based Modelling Study. PLoS Med 10(10): e32767. doi:10.1371/journal.pmed.1001542
Kategorie: Research Article
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.pmed.1001542

Souhrn

Zdroje

1. Joint United Nations Programme on HIV/AIDS (2012) UNAIDS report on the global AIDS epidemic. Geneva: Joint United Nations Programme on HIV/AIDS.

2. SutcliffeCG, van DijkJH, BoltonC, PersaudD, MossWJ (2008) Effectiveness of antiretroviral therapy among HIV-infected children in sub-Saharan Africa. Lancet Infect Dis 8: 477–489.

3. World Health Organization (2010) Antiretroviral therapy of HIV infection in infants and children: towards universal access: recommendations for a public health approach—2010 revision. Geneva: World Health Organization.

4. SauvageotD, SchaeferM, OlsonD, Pujades-RodriguezM, O'BrienDP (2010) Antiretroviral Therapy Outcomes in Resource-Limited Settings for HIV-Infected Children 5 Years of Age. Pediatrics 125: e1039–e1047.

5. de BeaudrapP, RouetF, FassinouP, KouakoussuiA, MercierS, et al. (2008) CD4 cell response before and after HAART initiation according to viral load and growth indicators in HIV-1-infected children in Abidjan, Cote d'Ivoire. J Acquir Immune Defic Syndr 49: 70–76.

6. RouetF, FassinouP, InwoleyA, AnakyM-F, KouakoussuiA, et al. (2006) Long-term survival and immuno-virological response of African HIV-1-infected children to highly active antiretroviral therapy regimens. AIDS 20: 2315–2319.

7. Kariyo PC, Mbuzenakamwe MJ, Baramperanye E, Barutwanayo L, Nyatanyi J, et al.. (2006) Antiretroviral therapy in a hundred Burundian children with AIDS [abstract]. Abstract number MOPE0208. AIDS 2006—XVI International AIDS Conference; 13–18 Aug 2006; Toronto, Ontario, Canada.

8. Anabwani GM, Lowenthal MM, Jibril HB, Sechele M, Schwarzwald H, et al.. (2006) Long term response to highly active antiretroviral therapy among treatment naïve children in Botswana [abstract]. Abstract number MOPE0261. AIDS 2006—XVI International AIDS Conference; 13–18 Aug 2006; Toronto, Ontario, Canada.

9. DART Trial Team (2010) Routine versus clinically driven laboratory monitoring of HIV antiretroviral therapy in Africa (DART): a randomised non-inferiority trial. Lancet 375: 123–31.

10. AchhraAC, PhanuphakP, AminJ (2011) Long-term immunological outcomes in treated HIV-infected individuals in high-income and low-middle income countries. Curr Opin HIV AIDS 6: 258–265.

11. GibbDM, NewberryA, KleinN, De RossiA, Grosch-WoernerI, et al. (2000) Immune repopulation after HAART in previously untreated HIV-1-infected children. Lancet 355: 1331–1332.

12. ResinoS, SeoaneE, PérezA, Ruiz-MateosE, LealM, et al. (2006) Different profiles of immune reconstitution in children and adults with HIV-infection after highly active antiretroviral therapy. BMC Infect Dis 6: 112.

13. SleasmanJW, NelsonRP, GoodenowMM, WilfretD, HutsonA, et al. (1999) Immunoreconstitution after ritonavir therapy in children with human immunodeficiency virus infection involves multiple lymphocyte lineages. J Pediatr 134: 597–606.

14. The Collaboration of Observational HIV Epidemiological Research Europe (COHERE) Study Group (2008) SabinCA, SmithCJ, d'Arminio MonforteA, BattegayM, et al. (2008) Response to combination antiretroviral therapy: variation by age. AIDS 22: 1463–1473.

15. BainsI, ThiebautR, YatesAJ, CallardR (2009) Quantifying thymic export: combining models of naive T cell proliferation and TCR excision circle dynamics gives an explicit measure of thymic output. J Immunol 183: 4329–4336.

16. De RossiA, WalkerAS, KleinN, ForniDD, KingD, et al. (2002) Increased thymic output after initiation of antiretroviral therapy in human immunodeficiency virus type 1-infected children in the Paediatric European Network for Treatment of AIDS (PENTA) 5 trial. J Infect Dis 186: 312–320.

17. SteinmannGG, KlausB, Muller-HermelinkH-K (1985) The involution of the ageing human thymic epithelium is independent of puberty. Scand J Immunol 22: 563–575.

18. ThiebautR, Jacqmin-GaddaH, WalkerS, SabinC, PrinsM, et al. (2006) Determinants of response to first HAART regimen in antiretroviral-naive patients with an estimated time since HIV seroconversion. HIV Med 7: 1–9.

19. LewisJ, WalkerAS, CastroH, De RossiA, GibbDM, et al. (2012) Age and CD4 count at initiation of antiretroviral therapy in HIV-infected children: effects on long-term T-cell reconstitution. J Infect Dis 205: 548–556.

20. ARROW Trial Team (2013) KekitiinwaA, CookA, NathooK, MugyenyiP, et al. (2013) ARROW: a 5-year randomised factorial trial of routine vs clinically driven laboratory monitoring and first-line antiretroviral therapy strategies in HIV-infected African children. Lancet 381: 1391–1403.

21. National Institutes of Health Division of AIDS (2009) Division of AIDS table for grading the severity of adverse events, version 1.0, December, 2004; clarification August 2009. Available: http://rsc.tech-res.com/Document/safetyandpharmacovigilance/Table_for_Grading_Severity_of_Adult_Pediatric_Adverse_Events.pdf. Accessed 24 September 2013.

22. HulstaertF, HannetI, DeneysV, MunhyeshuliV, ReichertT, et al. (1994) Age-related changes in human blood lymphocyte subpopulations. Clin Immunol Immunopathol 70: 152–158.

23. HueneckeS, BehlM, FadlerC, ZimmermannSY, BochennekK, et al. (2008) Age-matched lymphocyte subpopulation reference values in childhood and adolescence: application of exponential regression analysis. Eur J Haematol 80: 532–539.

24. WadeAM, AdesAE (1994) Age related reference ranges: significance tests for models and confidence intervals for centiles. Stat Med 13: 2359–2367.

25. PatelK, HernanMA, WilliamsPL, SeegerJD, McIntoshK, et al. (2008) Long-term effects of highly active antiretroviral therapy on CD4+ cell evolution among children and adolescents infected with HIV: 5 years and counting. Clin Infect Dis 46: 1751–1760.

26. ResinoS, CorreaR, BellonJM, Sanchez-RamonS, Muñoz-FernándezMÁ (2002) Characterizing immune reconstitution after long-term highly active antiretroviral therapy in pediatric AIDS. AIDS Res Hum Retroviruses 18: 1395–1406.

27. HIV Paediatric Prognostic Markers Collaborative Study (2010) BoydK, DunnDT, CastroH, GibbDM, et al. (2010) Discordance between CD4 cell count and CD4 cell percentage: implications for when to start antiretroviral therapy in HIV-1 infected children. AIDS 24: 1213–1217.

28. ColeTJ, FreemanJV, PreeceMA (1998) British 1990 growth reference centiles for weight, height, body mass index and head circumference fitted by maximum penalized likelihood. Stat Med 17: 407–429.

29. R Development Core Team (2011) R: a language and environment for statistical computing [computer program]. Vienna: R Foundation for Statistical Computing.

30. Pinheiro J, Bates D, DebRoy S, Sarkar D, R Development Core Team (2011) nlme: linear and nonlinear mixed effects models. Vienna: R Foundation for Statistical Computing.

31. Wolfram Research (2008) Mathematica 7.0 [computer program]. Champaign (Illinois): Wolfram Research.

32. PakkerNG, NotermansDW, de BoerRJ, RoosMTL, de WolfF, et al. (1998) Biphasic kinetics of peripheral blood T cells after triple combination therapy in HIV-1 infection: a composite of redistribution and proliferation. Nat Med 4: 208–214.

33. WalkerAS, DoerholtK, SharlandM, GibbDM (2004) for the Collaborative HIV Paediatric Study (CHIPS) Steering Committee (2004) Response to highly active antiretroviral therapy varies with age: the UK and Ireland Collaborative HIV Paediatric Study. AIDS 18: 1915–1924.

34. van RossumAMC, ScherpbierHJ, van LochemEG, PakkerNG, SliekerWAT, et al. (2001) Therapeutic immune reconstitution in HIV-1-infected children is independent of their age and pretreatment immune status. AIDS 15: 2267–2275.

35. HainautM, DucarmeM, SchandeneL, PeltierCA, MarissensD, et al. (2003) Age-related immune reconstitution during highly active antiretroviral therapy in human immunodeficiency virus type 1-infected children. Pediatr Infect Dis J 22: 62–69.

36. The Antiretroviral Therapy Cohort Collaboration (ART-CC) (2009) LanoyE, MayM, MocroftA, PhillipA, et al. (2009) Prognosis of patients treated with cART from 36 months after initiation, according to current and previous CD4 cell count and plasma HIV-1 RNA measurements. AIDS 23: 2199–2208.

37. LichtensteinKA, ArmonC, BuchaczK, ChmielJS, BucknerK, et al. (2010) Low CD4+ T cell count is a risk factor for cardiovascular disease events in the HIV Outpatient Study. Clin Infect Dis 51: 435–447.

38. TriantVA, ReganS, LeeH, SaxPE, MeigsJB, et al. (2010) Association of immunologic and virologic factors with myocardial infarction rates in a U.S. health care system. J Acquir Immune Defic Syndr 55: 615–619.

39. GuiguetM, BouéF, CadranelJ, LangJ-M, RosenthalE, et al. (2009) Effect of immunodeficiency, HIV viral load, and antiretroviral therapy on the risk of individual malignancies (FHDH-ANRS CO4): a prospective cohort study. Lancet Oncol 10: 1152–1159.

40. ThiebautR, Jacqmin-GaddaH, LeportC, KatlamaC, CostagliolaD, et al. (2003) Bivariate longitudinal model for the analysis of the evolution of HIV RNA and CD4 cell count in HIV infection taking into account left censoring of HIV RNA measures. J Biopharm Stat 13: 271–282.